And, and there's a lot of, lot of control in regards to the behavior of the cancer that exists within that environment.

That's right.

So, so here- here's, I, I think, a, um, a way to, to, to envision what is happening in a way that gives it greater access to treatment.

So the focus, by definition, there, there's a, a, a basic stipulation that we always consider, and that this approach is always in addition to whatever the conventional oncology treatment is that the patient is receiving, not instead of.

And so that, it's a separate...

You can think of it as a separate parallel track that is aimed at additional anti-cancer support from the evidence base.

And I think it's important to acknowledge that the medical oncology subspecialty, if you think of the medical profession as a big medical union with trades and sub-trades called specialties and subspecialties, that the medical oncology subspecialty, the radiation oncology subspecialty, they are using the best science we have, the top of the data mountain, the, the gold standard from clinical trials, and that's the, the, called the standard of care.

And so if you don't shift that, that biology, that, that kind of molecular signaling that's taking place, then essentially you are still having the same kind of foundation that created the cancer in the first place.